[go: up one dir, main page]

Hao et al., 2022 - Google Patents

Iridium (III) complexes induce cervical carcinoma apoptosis via disturbing cellular redox homeostasis disorder and inhibiting PI3K/AKT/mTOR pathway

Hao et al., 2022

Document ID
14204840936263367
Author
Hao J
Liu H
Wang J
Wang X
Huang C
Liang L
Chen J
Wang Y
Liu Y
Publication year
Publication venue
Journal of Inorganic Biochemistry

External Links

Snippet

Improvement of antineoplastic activity and selectivity is a main goal in the development of antineoplastic agents. Herein, we synthesized three new iridium (III) complexes:[Ir (ppy) 2 (FTTP)](PF 6)(Ir1, ppy= 2-phenylpyridine, FTTP= 2-(3-fluoronaphthalen-2-yloxy)-1, 4, 8, 9 …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0073—Rhodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals

Similar Documents

Publication Publication Date Title
Hao et al. Iridium (III) complexes induce cervical carcinoma apoptosis via disturbing cellular redox homeostasis disorder and inhibiting PI3K/AKT/mTOR pathway
Wan et al. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption
Xing et al. A fluorogenic ONOO–-triggered carbon monoxide donor for mitigating brain ischemic damage
Liu et al. Synthesis, characterization, and in vitro studies of bis [1, 3-diethyl-4, 5-diarylimidazol-2-ylidene] gold (I/III) complexes
Li et al. Polypyridyl Ruthenium (II) complex-induced mitochondrial membrane potential dissipation activates DNA damage-mediated apoptosis to inhibit liver cancer
Bai et al. Liposomes encapsulated iridium (III) polypyridyl complexes enhance anticancer activity in vitro and in vivo
Chen et al. A lysosome-targeted ruthenium (II) polypyridyl complex as photodynamic anticancer agent
CN101948488B (en) Ruthenium-selenium coordination compound and application thereof in preparing fluorescent probe and antineoplastic medicine
Du et al. Design, synthesis and biological evaluation of iridium (III) complexes as potential antitumor agents
Hao et al. Evaluation of anticancer effects in vitro of new iridium (III) complexes targeting the mitochondria
Liang et al. Synthesis and characterization of polypyridine ruthenium (II) complexes and anticancer efficacy studies in vivo and in vitro
MD4626C1 (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
Yuan et al. Synthesis and anticancer activity in vitro and in vivo evaluation of iridium (III) complexes on mouse melanoma B16 cells
Gu et al. Exploring anticancer efficiency of mitochondria-targeted cyclometalated iridium (III) complexes
Haribabu et al. Synthesis, cytotoxicity and docking studies (with SARS-CoV-2) of water-soluble binuclear Ru-p-cymene complex holding indole thiosemicarbazone ligand
Ol’shevskaya et al. Novel boronated derivatives of 5, 10, 15, 20-tetraphenylporphyrin: synthesis and toxicity for drug-resistant tumor cells
Zhou et al. Iridium (III)-BBIP complexes induce apoptosis via PI3K/AKT/mTOR pathway and inhibit A549 lung tumor growth in vivo
Hu et al. Synthesis, RNA-sequence and evaluation of anticancer efficacy of ruthenium (II) polypyridyl complexes toward HepG2 cells
Liu et al. DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions
Li et al. Influence of the Introduction of a Triphenylphosphine Group on the Anticancer Activity of a Copper Complex
Liu et al. The anticancer application of half-sandwich iridium (III) ferrocene-thiosemicarbazide Schiff base complexes
Zhu et al. Design, synthesis and biological evaluation of vinyl selenone derivatives as novel microtubule polymerization inhibitors
Jiang et al. Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes
Gu et al. Synthesis, crystal structure, spectroscopic characterization and anti-fungal activity of Ethyl 2-Oxo-2H-chromene-3-carboxylateDerivatives
Wang et al. Anticancer effect evaluation of iridium (III) complexes targeting mitochondria and endoplasmic reticulum